Among these, variants in PNPLA3 (patatin-like phospholipase domain-containing 3), TM6SF2 (transmembrane 6 superfamily member 2), MBOAT7 (membrane-bound O-acyltransferase domain-containing 7), and GCKR (glucokinase regulator) have been demonstrated to influence lipid metabolism and hepatic steatosis risk [15,16,17]. This evidence concerns the gene TM6SF2 and fatty liver disease.